Hormonal Research

Melanotan I
Afamelanotide — UV-Independent Tanning Research

Melanotan I (afamelanotide) is a synthetic analogue of alpha-MSH that selectively activates MC1R — the melanocortin receptor responsible for eumelanin production in melanocytes. Unlike Melanotan II, it doesn't activate MC3R/MC4R, giving it a cleaner, photoprotection-focused profile without the sexual arousal or appetite effects of its analogue.

MelanocortinTanningMC1RPhotoprotectionAfamelanotideErythropoietic Protoporphyria

At a Glance

CAS Number
75921-69-6
Molecular Weight
1,646.9 Da
Class
13 Amino Acids — α-MSH analogue
Published Studies
Substantial preclinical + clinical
Stability
Moderate — cold storage
Research Status
FDA approved (Scenesse) for EPP
← Back to Research Library
Overview

MC1R activation drives melanocytes to produce eumelanin — the dark, UV-absorbing pigment that provides natural photoprotection. Melanotan I achieves melanogenesis without UV exposure, which has made it medically relevant for conditions where sun exposure triggers dangerous reactions.

FDA approval (as Scenesse) for erythropoietic protoporphyria (EPP) — a condition where sun exposure causes severe pain — validated the MC1R mechanism for photoprotection beyond cosmetic applications.

"Melanotan I is the selective MC1R agonist — photoprotection without the CNS effects. Its FDA approval for EPP established the melanocortin photoprotection mechanism in clinical medicine, not just cosmetic research."

Research interest extends to its potential in skin cancer prevention, photosensitivity disorders beyond EPP, and as a comparator to Melanotan II for isolating MC1R-specific effects from the broader melanocortin cascade.

Mechanism of Action

This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.

🔬

MC1R Selective Agonism

Selectively activates melanocortin 1 receptor on melanocytes — driving eumelanin synthesis without meaningful MC3R/MC4R activation.

🌑

Eumelanin Production

Stimulates the switch from phaeomelanin to eumelanin — the darker, UV-protective pigment that provides natural photoprotection.

🛡️

UV-Independent Photoprotection

Increases melanin density before UV exposure — providing pre-emptive photoprotection for conditions requiring sun avoidance.

🏥

EPP Photoprotection

Reduces the phototoxic skin reactions in erythropoietic protoporphyria — the validated clinical indication driving FDA approval.

Key Research Areas

Preclinical and clinical models have investigated this compound across a wide range of physiological contexts and tissue types.

  • Erythropoietic protoporphyria — FDA-approved indication for photoprotection
  • Photoprotection and skin cancer prevention research — UV-independent melanin induction
  • MC1R pathway characterization — selective vs non-selective melanocortin agonist comparison
  • Polymorphic light eruption and solar urticaria — photosensitivity condition research
  • Skin tanning mechanism — eumelanin vs phaeomelanin production and UV protection
  • Comparison with Melanotan II — MC1R selectivity vs broad melanocortin agonism
  • Melanoma biology — MC1R variants and melanoma risk research

Melanotan I's FDA approval and MC1R selectivity make it the reference compound for photoprotection and melanogenesis research.

Compound Comparison

Melanotan I vs II defines the selectivity spectrum of melanocortin research — selective MC1R photoprotection vs broad-spectrum CNS and melanogenesis activation.

Aspect Melanotan I Melanotan II Alpha-MSH (native)
Receptor Selectivity MC1R selective MC1R, MC3R, MC4R, MC5R All MCR subtypes
Tanning Effect Yes — eumelanin Yes — eumelanin Yes — eumelanin
Sexual Arousal None Significant None at physiological levels
FDA Status Approved — Scenesse (EPP) Not approved Endogenous — not a drug
Primary Research Use Photoprotection, EPP Tanning + sexual function Mechanistic baseline
Safety Profile in Research Studies

The following reflects findings from published preclinical and clinical safety assessments where available.


FDA approved for EPP — validated clinical mechanism with Phase 3 data


MC1R selective — no CNS arousal or appetite effects; cleaner research profile for photoprotection studies


Pre-emptive photoprotection mechanism — unique among photoprotection research approaches


Subdermal implant delivery in approved form — not injectable in the traditional sense; research SC protocols differ from approved route

Frequently Asked Questions
How does Melanotan I differ from Melanotan II?
+
Melanotan I is selective for MC1R — melanogenesis and photoprotection only. Melanotan II activates MC1R, MC3R, MC4R, and MC5R — adding sexual arousal, appetite reduction, and other CNS effects. They share tanning but diverge in everything else.
Why was it approved for EPP?
+
EPP (erythropoietic protoporphyria) is a rare disease where sun exposure causes severe, burning pain in the skin. Pre-emptive eumelanin production via Melanotan I reduces phototoxic reactions — enabling patients to tolerate some sun exposure. No other effective treatment existed.
Does Melanotan I cause sexual arousal?
+
No — this is the key selectivity difference. MC3R/MC4R activation (which Melanotan II does) is responsible for the sexual arousal effects. Melanotan I's MC1R selectivity means photoprotection without CNS sexual function effects.
Is it relevant for skin cancer prevention research?
+
Yes — UV-independent eumelanin induction before sun exposure could theoretically reduce UV damage and skin cancer risk. This is an active area of research, though the EPP indication was established first due to the clear unmet need.

This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026